Gastric Cancer Clinical Trials in Rochester, Minnesota

4 studies are recruiting for gastric cancer in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

    The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Rochester, Minnesota
    Locations
    311 in total
    Run by
    AstraZeneca

    See if you can join NCT07431281 on ClinicalTrials.gov

  2. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
    Locations
    11 in total
    Run by
    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

  3. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic, Rochester, Minnesota
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  4. Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

    This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Rochester, Minnesota
    Locations
    25 in total
    Run by
    AstraZeneca

    See if you can join NCT06005493 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.